These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 35409)

  • 1. Fibrinolytic activity of menstrual blood in normal and menorrhagic women and in women wearing the Lippes Loop and the Cu-T (200).
    Hefnawi F; Saleh A; Kandil O; El-Sheikha Z; Hassanein M; Askalani H
    Int J Gynaecol Obstet; 1979; 16(5):400-7. PubMed ID: 35409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrinolytic activity in utero and bleeding complications with intrauterine contraceptive devices.
    Bonnar J; Kasonde K; Haddon M; Hassanein MK; Allington MJ
    Br J Obstet Gynaecol; 1976 Feb; 83(2):160-4. PubMed ID: 148902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinogen-fibrin degradation products in menstrual blood from women with normal and excessive menstrual losses.
    Hahn L; Rybo G
    Acta Obstet Gynecol Scand; 1975; 54(2):119-27. PubMed ID: 1136717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coagulation factors and fibrinolytic proteins in menstrual fluid collected from normal and menorrhagic women.
    Rees MC; Cederholm-Williams SA; Turnbull AC
    Br J Obstet Gynaecol; 1985 Nov; 92(11):1164-8. PubMed ID: 2415154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative quantitation of menstrual blood loss with the Lippes Loop, Dalkon Shield, and copper T intrauterine devices.
    Israel R; Shaw ST; Martin MA
    Contraception; 1974 Jul; 10(1):63-71. PubMed ID: 4442266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the correlation between local fibrinolytic activity in menstrual fluid and total blood loss during menstruation and effects of desmopressin.
    Edlund M; Blombäck M; He S
    Blood Coagul Fibrinolysis; 2003 Sep; 14(6):593-8. PubMed ID: 12960614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrin and platelets in menstrual discharge before and after the insertion of an intrauterine contraceptive device.
    Christiaens GC; Sixma JJ; Haspels AA
    Am J Obstet Gynecol; 1981 Aug; 140(7):793-98. PubMed ID: 7258261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood coagulation, fibrinolysis and plasma proteins in women with normal and with excessive menstrual blood loss.
    Hahn L; Cederblad G; Rybo G; Pehrsson NG; Bengtsen KK
    Br J Obstet Gynaecol; 1976 Dec; 83(12):974-80. PubMed ID: 1009035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrin degradation products in sera of women with normal menstruation and menorrhagia.
    Basu HK
    Br Med J; 1970 Jan; 1(5688):74-5. PubMed ID: 5411448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No increased systemic fibrinolysis in women with heavy menstrual bleeding.
    Wiewel-Verschueren S; Knol HM; Lisman T; Bogchelman DH; Kluin-Nelemans JC; van der Zee AG; Mulder AB; Meijer K
    J Thromb Haemost; 2014 Sep; 12(9):1488-93. PubMed ID: 24954113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consumption of fibrinolytic proteins in menstrual fluid from women with normal menstrual blood loss.
    Cederholm-Williams SA; Rees MC; Turnbull AC
    J Clin Pathol; 1984 Aug; 37(8):879-81. PubMed ID: 6540788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The response of endometrial blood vessels to intrauterine contraceptive devices: an electron microscopic study.
    Sheppard BL; Bonnar J
    Br J Obstet Gynaecol; 1980 Feb; 87(2):143-54. PubMed ID: 7362802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of tranexamic acid on measured menstrual loss and endometrial fibrinolytic enzymes in dysfunctional uterine bleeding.
    Gleeson NC; Buggy F; Sheppard BL; Bonnar J
    Acta Obstet Gynecol Scand; 1994 Mar; 73(3):274-7. PubMed ID: 8122512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Menstrual blood loss and fibrin degradation products.
    Cole SK; Clarkson AR
    Br Med J; 1972 Jan; 1(5792):78-9. PubMed ID: 5007072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased fibrinolytic activity in the endometrium of patients using copper-iud (gravigard).
    Larsson B; Liedholm P; Astedt B
    Int J Fertil; 1975; 20(2):77-80. PubMed ID: 3481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of menstrual flow by weighing protective pads in women with normal, decreased or increased menstruation.
    Gudmundsdottir BR; Hjaltalin EF; Bragadottir G; Hauksson A; Geirsson RT; Onundarson PT
    Acta Obstet Gynecol Scand; 2009; 88(3):275-9. PubMed ID: 19137461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of prostaglandins in IUD-associated uterine bleeding--effect of a prostaglandin synthetase inhibitor (ibuprofen).
    Roy S; Shaw ST
    Obstet Gynecol; 1981 Jul; 58(1):101-6. PubMed ID: 7243136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of fibrinolytic enzymes by macrophages on intrauterine contraceptive devices.
    Foley ME; Jenkins DM; McNicol GP
    Br J Obstet Gynaecol; 1978 Jul; 85(7):551-6. PubMed ID: 678491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The fibrinolytic enzyme system in normal menstruation and excessive uterine bleeding and the effect of tranexamic acid.
    Dockeray CJ; Sheppard BL; Daly L; Bonnar J
    Eur J Obstet Gynecol Reprod Biol; 1987 Apr; 24(4):309-18. PubMed ID: 2953634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormonal profile in IUD users.
    Souka AR; Rahman H; Osman M; Mohei Y; Rizk M
    Contracept Deliv Syst; 1981 Oct; 2(4):303-10. PubMed ID: 12336991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.